NCT06911788View on ClinicalTrials.gov

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

May 23, 2025

Study Completion Date

June 13, 2025

Conditions
Healthy Participants
Interventions
DRUG

Vepdegestrant (Reference)

Participants will receive a single intravenous (IV) dose of Vepdegestrant on Period 1 Day 1

DRUG

Vepdegestrant (Test)

Participants will receive a 200 mg single oral dose of Vepdegestrant tablet formulation on Period 2 Day 1

Trial Locations (2)

9728 NZ

ICON, Groningen

3584 BL

ICON - screening centre, Utrecht

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT06911788 - A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults | Biotech Hunter | Biotech Hunter